Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy

被引:7
作者
Yakushijin, Yoshihiro [1 ]
Shikata, Hisaharu [2 ]
Takaoka, Ikue [2 ]
Horikawa, Tamami [2 ]
Takeuchi, Kazuhito [2 ]
Yamanouchi, Jun [2 ]
Azuma, Taichi [2 ]
Narumi, Hiroshi [2 ]
Hato, Takaaki [3 ]
Yasukawa, Masaki [2 ]
机构
[1] Ehime Univ, Grad Sch Med, Ctr Canc, Ehime Univ Hosp, Toon, Ehime 7910295, Japan
[2] Ehime Univ, Grad Sch Med, Dept Bioregulatory Med, Toon, Ehime 7910295, Japan
[3] Ehime Univ, Grad Sch Med, Div Blood Transfus & Cell Therapy, Toon, Ehime 7910295, Japan
关键词
Granulocyte colony-stimulating factors (G-CSF); Cost-benefit; Febrile neutropenia (FN); R-CHOP; Non-Hodgkin lymphoma (NHL); RECEIVING CHEMOTHERAPY; DAILY FILGRASTIM; DOSE-INTENSITY; PEGFILGRASTIM; LENOGRASTIM; TRANSPLANTATION; LYMPHOMA; UPDATE;
D O I
10.1007/s10147-010-0134-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 mu g) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 mu g) was administered every other day to the other half of the patients when leukocytopenia (< 1.5 x 10(9)/L) and/or neutropenia (< 0.5 x 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed. No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF. We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 22 条
[1]   Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: A randomized study in patients undergoing autologous peripheral stem cell transplantation [J].
Ataergin, Selmin ;
Arpaci, Fikret ;
Turan, Mustafa ;
Solchaga, Luis ;
Cetin, Turker ;
Ozturk, Mustafa ;
Ozet, Ahmet ;
Komurcu, Seref ;
Ozturk, Bekir .
AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (08) :644-648
[2]   Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim [J].
Balducci, Lodovico ;
Al-Halawani, Hafez ;
Charu, Veena ;
Tam, Jennifer ;
Shahin, Seta ;
Dreiling, Lyndah ;
Ershler, William B. .
ONCOLOGIST, 2007, 12 (12) :1416-1424
[3]  
Carulli G, 1997, HAEMATOLOGICA, V82, P606
[4]  
Crawford Jeffrey, 2008, J Natl Compr Canc Netw, V6, P109
[5]   Lenograstim - An update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings [J].
Dunn, CJ ;
Goa, KL .
DRUGS, 2000, 59 (03) :681-717
[6]   THE EFFECT OF CYTOKINES ON THE EXPRESSION AND FUNCTION OF FC-RECEPTORS FOR IGG ON HUMAN MYELOID CELLS [J].
ERBE, DV ;
COLLINS, JE ;
SHEN, L ;
GRAZIANO, RF ;
FANGER, MW .
MOLECULAR IMMUNOLOGY, 1990, 27 (01) :57-67
[7]   A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy [J].
Green, MD ;
Koelbl, H ;
Baselga, J ;
Galid, A ;
Guillem, V ;
Gascon, P ;
Siena, S ;
Lalisang, RI ;
Samonigg, H ;
Clemens, MR ;
Zani, V ;
Liang, BC ;
Renwick, J ;
Piccart, MJ .
ANNALS OF ONCOLOGY, 2003, 14 (01) :29-35
[8]   Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer [J].
Holmes, FA ;
O'Shaughnessy, JA ;
Vukelja, S ;
Jones, SE ;
Shogan, J ;
Savin, M ;
Glaspy, J ;
Moore, M ;
Meza, L ;
Wiznitzer, I ;
Neumann, TA ;
Hill, LR ;
Liang, BC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :727-731
[9]  
KERST JM, 1993, BLOOD, V82, P3265
[10]   Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy [J].
Kim, IH ;
Park, SK ;
Suh, OK ;
Oh, JM .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (08) :753-759